Impact of Highly Active Antiretroviral Therapy on the Presenting Features and Outcome of Patients with Acquired Immunodeficiency Syndrome-Related Kaposi Sarcoma

Cancer

Volumn 98, Issue 11, 2003, Pages 2440-2446

  Nasti, Guglielmo ^a   Martellotta, Ferdinando ^a   Berretta, Massimiliano ^a   Mena, Maurizio ^b   Fasan, Marco ^c   Di Perri, Giovanni ^d   Talamini, Renato ^a   Pagano, Gabriella ^e   Montroni, Maria ^f   Cinelli, Roberta ^a   Vaccher, Emanuela ^a   Monforte, Antonella D'Arminio ^c   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Ospedale di Cuggiono   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d BORGO TRENTO HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Highly active antiretroviral therapy; Kaposi sarcoma; Natural history

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; NAVELBINE; PACLITAXEL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0344412949     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11816     Document Type: Article

References (15)

1. Brodt HR, Kamps BS, Gute P. Changing incidence of AIDS-defining illness in the era of antiretroviral combination therapy. AIDS. 1997;11:1731-1738.
2. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. J Acquir Immune Defic Syndr. 1999;21:S34-S41.
3. Jones JL, Hanson DL, Dworkin MS, et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr. 1999;21:S11-S17.
4. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS. 2000;14:987-993.
5. Vaccher E, di Gennaro G, Nasti G, et al. HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy. J Acquir Immune Defic Syndr. 1999;22:407-408.
6. Cattelan AM, Calabro ML, Aversa SM, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer. 1999;15:1809-1815.
7. Dezube BJ. New therapies for the treatment of AIDS-related Kaposi's sarcoma. Curr Opin Oncol. 2000;12:445-449.
8. Tavio M, Nasti G, Spina M, et al. Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Ann Oncol. 1998;9:923.
9. Lebbé C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998;12:F45-F49.
10. Nasti G, Errante D, Santarossa S, et al. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. Drug Saf. 1999;20:403-425.
11. Ensoli B, Stürzl M. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev. 1998;9:63-83.
12. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. J Clin Oncol. 1989;7:1201-1207.
13. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481
14. Tam HK, Zhang ZF, Jacobson LP, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi's sarcoma or non-Hodgkin's lymphoma. Int J Cancer. 2002;98:916-922.
15. Bower M, Fox P, Fife K, et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS. 1999;13:2105-2111.